证券代码：301206 证券简称：三元生物 公告编号：2025-052 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司 重点内容提示： 户中的股份 1,875,700 股不参与本次权益分派。公司 2024 年年度权益分派方案为： 以公司现有总股本 202,325,700 股剔除已回购股份 1,875,700 股后的总股本 一年度。 总股本保持不变，现金红利总金额分摊到每一股的比例将减小，因此计算除权除 息价格时，按公司总股本（含回购股份）折算的每股现金红利（含税）=现金红 利总额÷总股本（含回购股份）= （202,325,700 股-1,875,700 股）÷10 股×10.00 元/股 ÷202,325,700 股≈0.9907293 元（保留七位小数，最后一位直接截取，不 四舍五入） 。本次权益分派实施后的除权除息参考价=除权除息日前一交易日收盘 价 - 按 公司 总股 本 折算 的 每 股现 金红 利 =除 权 除 息日 前一 交 易日 收 盘 价 -0. 公司 2024 年年度权益分派方案已获 2025 年 5 月 26 ...

山东三元生物科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：301206 证券简称：三元生物 公告编号：2025-052 重点内容提示： 1、山东三元生物科技股份有限公司（以下简称"公司"）回购专用证券账 户中的股份1,875,700股不参与本次权益分派。公司2024年年度权益分派方案为： 以公司现有总股本 202,325,700 股剔除已回购股份 1,875,700 股后的总股本 200,450,000 股为基数，向全体股东每 10 股派 10.00 元（含税），共计派发 200,450,000 元，不送红股，不以资本公积金转增股本，剩余未分配利润结转下 一年度。 2、本次权益分派实施后，根据股票市值不变原则，实施权益分派前后公司 总股本保持不变，现金红利总金额分摊到每一股的比例将减小，因此计算除权除 息价格时，按公司总股本（含回购股份）折算的每股现金红利（含税）=现金红 利总额÷总股本（含回购股份）= [（202,325,700 股-1,875,700 股）÷10 股×10.00 元/股] ÷2 ...

山东三元生物科技股份有限公司 证券代码：301206 证券简称：三元生物 公告编号：2025-053 1 / 3 二、调整回购股份价格上限的原因 关于 2024 年度权益分派实施后调整回购价格上限的公 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、调整前回购股份价格上限：不超过人民币 34.60 元/股（含） 2、调整后回购股份价格上限：不超过人民币 33.61 元/股（含） 3、回购股份价格上限调整生效日期：2025 年 6 月 6 日（权益分派除权除息 日） 一、回购股份的基本情况 山东三元生物科技股份有限公司（以下简称"公司"） 于 2024 年 7 月 8 日召开了第四届董事会第二十三次会议，会议审议通过了《关于回购公司股份方 案的议案》，同意公司使用自有资金以集中竞价交易方式回购公司已发行的部分 人民币普通股（A 股），用于后期实施股权激励或员工持股计划。本次回购资金 总额不低于人民币 5,000 万元（含），且不超过人民币 10,000 万元（含），回购 价格不超过 35 元/股（含），回购股份的实施期限自公司董事会审议通 ...

上市首日，三元生物创下上市以来最高价报146.00元。该股目前处于破发状态。 三元生物首次公开发行股票募集资金总额为36.86亿元，扣除发行费用后募集资金净额为35.47亿元。该 公司最终募集资金净额比原计划多26.47亿元。三元生物于2022年1月28日披露的招股说明书显示，该公 司拟募集资金9.00亿元，分别用于年产50000吨赤藓糖醇及技术中心项目、研发信息中心建设项目、补 充流动资金。 中国经济网北京5月28日讯三元生物（301206）(301206.SZ)今日股价下跌，截至收盘报29.60元，跌幅 3.58%。 三元生物于2022年2月10日在深交所创业板上市，公开发行3372.10万股，发行价格为109.30元/股，保荐 机构(主承销商)为中信建投（601066）证券股份有限公司，保荐代表人为陆丹君、陈磊。 2022年6月10日，三元生物披露了2021年年度权益分派实施公告。公司2021年年度权益分派方案为：以 公司现有总股本1.35亿股为基数，向全体股东每10股派10元现金(含税)，同时，以资本公积金向全体股 东每10股转增5股。分红前公司总股本为1.35亿股，分红后总股本增至2.02亿股。本次 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-051 山东三元生物科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议时间：2025 年 5 月 26 日（星期一）15:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 5 月 26 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券交易 所互联网投票系统的具体时间为：2025 年 5 月 26 日 9:15 至 15:00 2、会议召开地点：山东省滨州市滨北梧桐十路 101 号三元生物公司会议室 3、会议召开方式：现场表决和网络表决相结合的方式 4、会议召集人：董事会 5、会议主持人：董事长聂在建 6、召开情况合法、合规、合章程性说明：本次会议的召集、召开与表决程 序符合《公司法》《深圳证券交易所 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于山东三元生物科技股份有限公司 2024 年年度股东大会的 致：山东三元生物科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见证 贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律业务管 理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法律业务 执业规则》"）等相关法律、行政法规、规章、规范性文件及《山东三元生物科技股份有 限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集 人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如 ...

Core Viewpoint - Binzhou City is committed to implementing the "industrial city, manufacturing strong city" strategy, focusing on transforming traditional industries, promoting emerging industries, and developing a modern industrial system with strong support [1][16]. Group 1: Industrial Development - Binzhou has cultivated five trillion-level pillar industries, four strategic emerging industries, and three future industries, establishing a matrix of industrial development [1][16]. - The city has built two provincial advanced manufacturing clusters and seven provincial characteristic industrial clusters, maintaining its position as one of the top 100 advanced manufacturing cities in the country for four consecutive years [1][16]. - In 2024, the revenue for high-end aluminum, fine chemicals, and intelligent textile industry clusters is projected to reach 471.1 billion yuan, 241.3 billion yuan, and 192 billion yuan respectively, showcasing the strong momentum of industrial transformation [1][16]. Group 2: Economic Performance - Binzhou's GDP is expected to exceed 340 billion yuan in 2024, achieving a year-on-year growth of 6.2%, which is higher than the national average [4]. - The industrial output value above designated size is projected to grow by 9.6% year-on-year, with manufacturing growth at 11.8%, particularly in equipment manufacturing, which is expected to grow by 16.1% [6]. - High-tech manufacturing value added is expected to grow by 22.3%, significantly outpacing the average growth rate of industrial enterprises [6]. Group 3: Innovation and Technology - The number of national high-tech enterprises in Binzhou has surpassed 800, with a year-on-year growth of 21.3%, maintaining over 20% growth for three consecutive years [8]. - The city has approved 66 provincial-level technology projects, receiving 220 million yuan in financial support, marking a historical high [8]. - The establishment of the "Binzhou Aluminum Industry Advanced Manufacturing Provincial Laboratory" represents a significant breakthrough in innovation platform construction [8]. Group 4: Policy Framework - The "New Quality Productive Forces" concept has been incorporated into the national strategy, with Binzhou actively responding by implementing policies to foster innovation and industrial development [10][11]. - A series of forward-looking policies have been introduced to support the development of advanced manufacturing clusters and new generation information technology industries [11][14]. - The government aims to create a manufacturing strong city with core competitiveness by focusing on high-end, intelligent, green, and clustered industrial development [11][16]. Group 5: Future Trends - Binzhou is expected to strengthen traditional industry upgrades, particularly in high-end aluminum, and expand into new areas such as renewable energy and low-altitude economy [27][30]. - The integration of digital technology and intelligent manufacturing is anticipated to enhance industrial transformation, with plans to cultivate over 500 benchmark enterprises [29]. - The city aims to optimize its innovation ecosystem, enhancing collaboration between government, industry, academia, and research to boost technology transfer and innovation [31].

Group 1 - The sugar substitute concept is experiencing a decline in the afternoon trading session, with Baolingbao (002286) nearing a trading halt [1] - Other companies in the sector, including Sanyuan Bio (301206), Jinhai Bio (002688), Vinegar Chemical (603968), and Xinghuo Technology (600866), are also seeing a drop in stock prices [1] - There is an influx of dark pool funds entering these stocks, indicating potential interest from institutional investors [1]

Core Viewpoint - The U.S. Department of Commerce has announced preliminary results of anti-dumping and countervailing investigations on erythritol products from China, with Sanwei Biological (301206.SZ) facing a countervailing duty of 3.49% and other Chinese producers/exporters facing a rate of 3.47% [2] Group 1: Company Impact - Sanwei Biological acknowledged that the U.S. investigations have impacted its sales in the American market, and the extent of future impacts will depend on the progress of the investigations and market changes [3] - The company is implementing various measures to mitigate the effects, including adjusting sales strategies to focus on the domestic health consumer market and accelerating expansion into emerging markets in Southeast Asia, India, the Middle East, and along the Belt and Road Initiative [3] Group 2: Investigation Status - It is important to note that the countervailing investigation is not yet concluded, and the results are preliminary; the U.S. Department of Commerce will conduct further verification before making a final ruling, expected to be announced on September 24, 2025 [4] Group 3: Company Performance - In 2024, Sanwei Biological reported revenue of 713 million yuan, a year-on-year increase of 42.72%, and a net profit of 105 million yuan, up 87.47% year-on-year; foreign market revenue was 494 million yuan, representing a 33.18% increase and accounting for approximately 70% of total revenue [5] - In the first quarter of 2025, the company experienced a revenue decline of 21.73% year-on-year, totaling 150 million yuan, while net profit increased by 2.75% year-on-year to 24.91 million yuan, indicating a significant slowdown compared to 2024 [5]

Group 1: Company Performance and Market Conditions - The company is currently preparing for the launch of a glucose syrup production project with an annual capacity of 80,000 tons, which is still in the preparatory stage [6] - The company reported a significant impact from the EU's anti-dumping tariffs, with a 156.7% increase in tariffs affecting sales [3] - The company is actively seeking to diversify its market presence, particularly in Southeast Asia, South Korea, and Japan, to reduce reliance on the EU and US markets [8] Group 2: Product Development and Market Strategy - The company is focusing on the development of alternative sweeteners, such as allulose and tagatose, to meet the growing demand for healthier options [9] - The production capacity for allulose is currently 10,000 tons, with plans for an additional 10,000 tons under construction [19] - The company aims to capture a potential market of 770,000 tons per year by replacing just 1% of the global sugar consumption of 77 million tons [23] Group 3: Financial and Investment Strategies - The company has a high per-share reserve of 17.3859 yuan and is considering stock conversion options to enhance liquidity [8] - The company is exploring acquisition opportunities to strengthen its position in the synthetic biology sector and enhance its competitive edge [11] - The company is committed to maintaining its current production capacity for erythritol despite ongoing technological upgrades [20] Group 4: Regulatory and Compliance Issues - The company is closely monitoring the US anti-dumping investigation, with initial rulings expected by July 11, 2025 [4] - The company is adjusting its production processes in response to EU anti-dumping regulations and is working with legal experts to navigate these challenges [9] - The company is actively engaging with US clients to capitalize on recent tariff adjustments, aiming to secure more orders [18]